ATE210184T1 - Ungespleisste varianten des gp350/220 - Google Patents

Ungespleisste varianten des gp350/220

Info

Publication number
ATE210184T1
ATE210184T1 AT95916984T AT95916984T ATE210184T1 AT E210184 T1 ATE210184 T1 AT E210184T1 AT 95916984 T AT95916984 T AT 95916984T AT 95916984 T AT95916984 T AT 95916984T AT E210184 T1 ATE210184 T1 AT E210184T1
Authority
AT
Austria
Prior art keywords
protein
sequences
unspliced
variants
unspliced variants
Prior art date
Application number
AT95916984T
Other languages
English (en)
Inventor
Richard Spaete
Winthrop T Jackman
Original Assignee
Aviron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aviron Inc filed Critical Aviron Inc
Application granted granted Critical
Publication of ATE210184T1 publication Critical patent/ATE210184T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Paper (AREA)
  • Fats And Perfumes (AREA)
  • Polarising Elements (AREA)
AT95916984T 1994-04-18 1995-04-13 Ungespleisste varianten des gp350/220 ATE210184T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
PCT/US1995/004611 WO1995028488A1 (en) 1994-04-18 1995-04-13 NON-SPLICING VARIANTS OF gp350/220

Publications (1)

Publication Number Publication Date
ATE210184T1 true ATE210184T1 (de) 2001-12-15

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916984T ATE210184T1 (de) 1994-04-18 1995-04-13 Ungespleisste varianten des gp350/220

Country Status (25)

Country Link
US (3) US6054130A (de)
EP (1) EP0769056B1 (de)
JP (4) JP3447743B2 (de)
KR (1) KR100380953B1 (de)
CN (2) CN1118573C (de)
AT (1) ATE210184T1 (de)
AU (1) AU707837B2 (de)
BR (1) BR9507473A (de)
CA (1) CA2187908C (de)
CZ (1) CZ292283B6 (de)
DE (1) DE69524415T2 (de)
DK (1) DK0769056T3 (de)
ES (1) ES2170144T3 (de)
FI (2) FI118224B (de)
HU (1) HU221647B1 (de)
LV (1) LV11803B (de)
MY (1) MY114769A (de)
NO (1) NO319382B1 (de)
PL (1) PL181881B1 (de)
PT (1) PT769056E (de)
RU (1) RU2178807C2 (de)
SK (1) SK283446B6 (de)
TW (1) TW496897B (de)
UA (1) UA47403C2 (de)
WO (1) WO1995028488A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
US6458939B1 (en) * 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
JP5138844B2 (ja) 1998-06-12 2013-02-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
US20100297612A1 (en) * 2009-05-22 2010-11-25 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of cytomegalovirus and epstein-barr virus
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051079B1 (de) * 1980-11-03 1984-09-26 Deutsche ITT Industries GmbH Binäres MOS-Ripple-Carry-Parallel-Addier/Subtrahierwerk und dafür geeignete Addier/Subtrahierstufe
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
EP0312164A1 (de) * 1987-10-16 1989-04-19 Merck & Co. Inc. Reinigung von rekombinanten Epstein-Barr-Virusantigenen von Vero-, Hefe- oder L-Zellen
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Also Published As

Publication number Publication date
PL316941A1 (en) 1997-02-17
JP2005333990A (ja) 2005-12-08
HUT75831A (en) 1997-05-28
KR100380953B1 (ko) 2003-10-10
HU221647B1 (hu) 2002-12-28
FI964186A0 (fi) 1996-10-18
US5824508A (en) 1998-10-20
AU2383895A (en) 1995-11-10
EP0769056B1 (de) 2001-12-05
FI118224B (fi) 2007-08-31
DE69524415D1 (de) 2002-01-17
CA2187908C (en) 2002-09-17
ES2170144T3 (es) 2002-08-01
MY114769A (en) 2003-01-31
NO319382B1 (no) 2005-07-25
DK0769056T3 (da) 2002-04-02
CN100415895C (zh) 2008-09-03
JP4317786B2 (ja) 2009-08-19
LV11803B (en) 1998-01-20
CA2187908A1 (en) 1995-10-26
SK134396A3 (en) 1997-06-04
JP2003230396A (ja) 2003-08-19
UA47403C2 (uk) 2002-07-15
EP0769056A1 (de) 1997-04-23
PL181881B1 (pl) 2001-09-28
JP3447743B2 (ja) 2003-09-16
EP0769056A4 (de) 1998-03-04
FI20075338A (fi) 2007-05-10
US6054130A (en) 2000-04-25
SK283446B6 (sk) 2003-07-01
CZ305496A3 (en) 1997-10-15
JPH10501687A (ja) 1998-02-17
NO964431D0 (no) 1996-10-18
FI964186A (fi) 1996-12-17
LV11803A (lv) 1997-06-20
CN1152940A (zh) 1997-06-25
PT769056E (pt) 2002-05-31
RU2178807C2 (ru) 2002-01-27
CN1495262A (zh) 2004-05-12
WO1995028488A1 (en) 1995-10-26
CN1118573C (zh) 2003-08-20
DE69524415T2 (de) 2002-08-01
CZ292283B6 (cs) 2003-08-13
US6458364B1 (en) 2002-10-01
TW496897B (en) 2002-08-01
JP2004290199A (ja) 2004-10-21
AU707837B2 (en) 1999-07-22
HU9602894D0 (en) 1996-12-30
NO964431L (no) 1996-12-11
BR9507473A (pt) 1997-09-23

Similar Documents

Publication Publication Date Title
FI20075338A (fi) gb350/220:n ei silmukoivia muutoksia
CA2263889A1 (en) P-selectin ligand proteins
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
AU2058888A (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof
ES8707974A1 (es) Procedimiento para la obtencion de un peptido
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
AU8258591A (en) Human mk gene and protein sequence
WO1995030001A3 (en) Novel p-selectin ligand protein
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
AU4034095A (en) Cyclohexapeptides and their mixtures, a process for preparing them, and their use
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
DE69534738D1 (de) Leukocyten-aktivierender Faktor
MX9504057A (es) Proteina que tiene actividad tpo.